SIGA Technologies, Inc. (SIGA) has a MoatMap StockRank of 82/100 based on Quality (68/100), Value (62/100), and Momentum (34/100) factor scores. The current signal is STRONG BUY. SIGA is a single-product health security company dependent on lumpy, unpredictable government procurement contracts for its antiviral TPOXX, lacking compounder characteristics.
SIGA Technologies, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for biodefense and emerging infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral treatment for smallpox, approved in the U.S. and E.U., and procured by governments globally for strategic stockpiles. This critical biodefense asset provides SIGA with a unique and essential market position, supported by government contracts.
| Price | $4.43 |
| Market Cap | $341M |
| P/E (TTM) | 15.82 |
| P/E (Forward) | 4.22 |
| Price/Book | 1.60 |
| Return on Equity | 11.0% |
| Return on Invested Capital | 11.8% |
| Debt/Equity | 0.40 |
| Gross Margin | 43.6% |
| Operating Margin | -85.2% |
| Revenue Growth | -11.3% |
| Free Cash Flow | $59M |
SIGA Technologies, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).